来曲唑单药治疗ER阳性激素反应性早期乳腺癌的效果及不良反应观察

目的 研究来曲唑单药治疗雌激素受体(ER)阳性激素反应性早期乳腺癌的效果及不良反应.方法 选择2009年2月至2010年2月本院70例早期ER阳性激素反应性乳腺癌患者作为研究对象,随机分为两组,每组35例.观察组行来曲唑单药治疗,对照组行他莫昔芬序贯来曲唑治疗,观察两组治疗效果及不良反应发生情况.结果 观察组近期总有效率为85.71％,对照组为82.86％,差异无统计学意义(P＞0.05).观察组1、3、5年存活率分别为94.29％、90.91％及83.33％,与对照组比较差异无统计学意义(P＞0.05).观察组治疗3年复发率为20.00％,显著低于对照组的46.43％,差异有统计学意义(P＜0.05).观察组高脂血症和关节疼痛发生率显著高于对照组,潮热、阴道出血及静脉血栓发生率显著低于对照组,差异均有统计学意义(P＜0.05).结论 来曲唑单药治疗ER阳性激素反应性早期乳腺癌效果显著,复发率低,临床应用时应充分评估复发风险和不良反应情况,坚持个体化治疗.

Observation on the effect and adverse reactions of letrozole monotherapy in early ER positive hormone responsive breast cancer

Objective To study the effect and adverse reactions of letrozole monotherapy in early estrogen receptor (ER) positive hormone responsive breast cancer.Methods 70 cases of early ER positive hormone responsive breast cancer who were admitted in our hospital between February 2009 and February 2010 were selected as the study object,and randomly divided into two groups,35 cases in each group.Observation group was treated with letrozole monotherapy,while control group was treated with sequential tamoxifen and letrozole therapy.The curative effect and the incidence of adverse reactions in two groups were observed.Results The short-term total effective rate in observation group was 85.71％,while that in control group was 82.86％ (P＞0.05).1,3,and 5-year survival rates in observation group were 94.29％,90.91％,and 83.33％,respectively,without statistically significant differences compared with those in control group (P＞0.05).3-year recurrence rate in observation group (20.00％) was significantly lower than that in control group (46.43％) (P＜0.05).The incidences of hyperlipidemia and joint pain in observation group were significantly higher than those in control group,while the incidences of hot flashes,vaginal bleeding,and venous thrombosis were significantly lower than those in control group (P＜0.05).Conclusions The curative effect of letrozole monotherapy in early ER positive hormone responsive breast cancer is significant,and the recurrence rate is low.In clinical application,the risk of recurrence and adverse reactions should be fully assessed,adhering to individualized treatment.